Cancer

China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI

Retrieved on: 
Saturday, February 17, 2024

TAICHUNG, Feb. 17, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) in Taiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud's generative AI technology, including MedLM, which is a large language model built on Med-PaLM 2, CMUH has developed a comprehensive "AI-assisted Physician" system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc. 

Key Points: 
  • Establishing a comprehensive "AI-assisted Physician" using generative AI from Google Cloud, including MedLM
    TAICHUNG, Feb. 17, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) in Taiwan announced its collaboration with Google Cloud in mid-December 2023.
  • Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in Taiwan.
  • MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best Healthcare AI models for the Chinese-speaking market in Asia.
  • In this remarkable era of gen AI, we are excited to collaborate with medical industry leaders that drive innovation through AI like CMUH, and partner with them to build the future of healthcare in Taiwan."

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

Retrieved on: 
Saturday, February 17, 2024

The following persons be elected as Directors with immediate effect: (i) Ms Nan Zhang; (ii) Ms Yun (Monica) Zhang; (iii) Mr Lui Chi Keung (Peter); (iv) Mr Jing Xian Li.

Key Points: 
  • The following persons be elected as Directors with immediate effect: (i) Ms Nan Zhang; (ii) Ms Yun (Monica) Zhang; (iii) Mr Lui Chi Keung (Peter); (iv) Mr Jing Xian Li.
  • As of the close of business on the EGM's record date of February 8, 2024, the Company had 188,327,959 ordinary shares issued and outstanding.
  • The results of the vote on each of the resolutions submitted for shareholder approval at the EGM were zero vote in favor and 97,272,542 votes against.
  • Further, Article 88 of the Articles permits a director to attend and be heard on any motion for his removal.

Melanoma Research Alliance Applauds FDA Approval of First Cellular Therapy in Melanoma

Retrieved on: 
Friday, February 16, 2024

WASHINGTON, Feb. 16, 2024 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics' AMTAGVI™ (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting.

Key Points: 
  • WASHINGTON, Feb. 16, 2024 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics' AMTAGVI™ (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting.
  • AMTAGVI is the first individualized Tumor Infiltrating Lymphocyte (TIL) therapy to earn FDA approval for any cancer.
  • After the TIL infusion, patients are treated with a therapy that stimulates the immune system to grow and divide.
  • "This groundbreaking T-cell immunotherapy represents a significant advancement in our ability to combat melanoma," says MRA Chief Executive Officer Marc Hurlbert, PhD.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, February 16, 2024

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on February 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees.

Key Points: 
  • SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on February 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees.
  • The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022 and May 10, 2023, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each of the stock options granted as referenced in this press release has an exercise price of $9.87, the closing price of Iovance’s common stock on the Date of Grant.
  • Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024

Retrieved on: 
Friday, February 16, 2024

To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e.

Key Points: 

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Retrieved on: 
Friday, February 16, 2024

"Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).

Key Points: 
  • "Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).
  • Melanoma can spread to other parts of the body if not detected and treated early, resulting in metastatic disease.
  • Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells.
  • Those patients whose melanoma has progressed with these therapies have a high unmet medical need.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

BostonGene Announces Publication in Nature

Retrieved on: 
Friday, February 16, 2024

BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.

Key Points: 
  • BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.
  • Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or “lymphocyte-depleted” tumor microenvironment (TME).
  • "BostonGene's innovative RNA-seq analytics lent novel insights into the dynamic changes associated with CAN-3110 therapy within the glioblastoma microenvironment," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
  • “Looking to the future, we are excited at the possibilities of harnessing oncolytic viruses to transform immunosuppressive microenvironments across a range of solid cancer types.”

MOJO Health Expands Personalized Holistic Health and Cancer Care Offerings with High-Quality Supplement Shop

Retrieved on: 
Friday, February 16, 2024

ATLANTA, Feb. 16, 2024 /PRNewswire-PRWeb/ -- MOJO Health is proud to announce the launch of its personalized high-quality supplement shop, furthering its mission to make holistic healthcare accessible to all and to evolve the cancer healing process to include the best of both conventional and traditional healing methodologies. Acknowledging the importance of supplement quality, MOJO Health has done the legwork for individuals facing cancer or serious diagnoses even beyond cancer to find the best in-kind supplements to increase their overall health and to learn how to potentially outmaneuver side effects.

Key Points: 
  • Acknowledging the importance of supplement quality, MOJO Health has done the legwork for individuals facing cancer or serious diagnoses even beyond cancer to find the best in-kind supplements to increase their overall health and to learn how to potentially outmaneuver side effects.
  • "I've worked with hundreds of cancer patients and can say unequivocally that patients who start with stronger vitality weather health challenge storms with much fewer headwinds," says Oscar Sierra, Chief Health Officer of MOJO Health.
  • The MOJO supplement shop follows the launch of MOJO Health's successful introduction of the holistic care Strategy Builder - a new-in-kind tool that empowers individuals facing cancer and side effects beyond cancer to create a personalized holistic strategy plan, in addition to their prescribed conventional treatment approach.
  • "I've worked with hundreds of cancer patients and can say unequivocally that patients who start with stronger vitality weather health challenge storms with much fewer headwinds," says Oscar Sierra, Chief Health Officer of MOJO Health.